Results were compared between cytology and surgical specimens, and interobserver concordance was assessed.
INTRODUCTION
Despite recent advances in the treatment of patients with non-small cell lung cancer (NSCLC), the overall 5-year survival rate has remained relatively steady at 18%. 1 Approximately 50% of patients with NSCLC present with advanced stage III or IV disease. 2, 3 For the majority of patients who have advanced NSCLC without a targetable driver mutation, the mainstay of therapy for the past 3 decades has been combination platinum-based cytotoxic chemotherapy. 4, 5 Immunotherapy is being used increasingly, and since 2015, the US Food and Drug Administration has approved 3 new checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor for the treatment of patients with advanced NSCLC: nivolumab, pembrolizumab, and atezolizumab. 6 The PD-1 receptor is a type I transmembrane cell receptor expressed primarily on activated mature T cells, B cells, monocytes, and other components of the immune system. 7 Binding of PD-1 to its ligands, programmed death-ligand 1 (PD-L1) or PD-L2, results in the inhibition of T-cell receptor-mediated lymphocyte proliferation through a variety of mechanisms, acting as a limiting factor in inflammatory responses and a mediator of peripheral tolerance. 7, 8 Disruption of the PD-1/PD-L1 interaction results in activation of the immune response and may play a role in the pathogenesis of several autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and others. 8, 9 The interaction of PD-1 and its ligands also has been shown to play an important role in the tumor microenvironment in several different malignancies, including NSCLC, leading to downregulation and apoptosis of tumor-reactive T cells. 10 Blockade of the PD-1/PD-L1 interaction leads to the increased activity of tumor neoantigen-specific CD8-positive T cells in the tumor microenvironment. 11, 12 Despite an increased understanding of PD-1 and its interactions on a molecular level, to the best of our knowledge, the prognostic role of PD-1/PD-L1 expression in malig nancy remains unclear. Studies correlating PD-1/ PD-L1 expression and prognosis in NSCLC have yielded variable results. 13, 14 However, it has become apparent that PD-L1 expression may be useful as a predictive biomarker, and treatment with monoclonal antibodies that block the PD-1/PD-L1 interaction has become an effective new immunotherapy, with initial studies reporting an overall objective durable response rate of 20% to 25% and a favorable side effect profile in patients with NSCLC, melanoma, and renal cell carcinoma. 15 Consequently, checkpoint inhibitors such as the PD-1 inhibitors pembrolizumab and nivolumab are increasingly being used as second-line treatment of patients with advanced NSCLC. 16, 17 A recent phase 3 clinical trial, OAK, also has demonstrated improved overall survival in previously treated patients with NSCLC using the PD-L1 inhibitor atezolizumab versus traditional chemotherapy. 18 In addition, first-line use of pembrolizumab as monotherapy or in combination with platinum-based chemotherapy has been approved for the treatment of patients with advanced stage nonsquamous NSCLC after recent phase 2 and 3 trials demonstrated significantly longer progression-free survival compared with traditional chemotherapy alone. 19, 20 The role of PD-L1 as a biomarker continues to be investigated, and to our knowledge a universal threshold for PD-L1 protein expression to determine treatment eligibility has not been established to date because clinical trials have studied different PD-1/PD-L1 inhibitors, different patient populations, and different immunohistochemical (IHC) assays to determine the optimal cutoff value. [16] [17] [18] [19] [20] Although some studies have suggested that anti-PD-1 and anti-PD-L1 treatment confers a survival benefit in certain patients regardless of tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression levels, 18, 19 the greatest benefit has been observed in patients with higher PD-L1 protein expression in both cell types. 19 Therefore, the use of PD-L1
IHC will likely continue to be studied as a potential predictor of response to immune checkpoint inhibitors in patients with NSCLC. Currently, the evaluation of PD-L1 expression in TCs and ICs typically is performed on surgical specimens because clinical trials and checkpoint inhibitor approval to date have required surgical biopsies for PD-L1 IHC. Nevertheless, in practice, the management of patients with advanced NSCLC is increasingly based on cytology sampling methods because they represent a minimally invasive method with which to obtain tissue for ancillary studies in medically vulnerable individuals. However, to our knowledge, robust studies examining the expression of PD-L1 in both TCs and ICs in cytology specimens with direct comparison to surgical specimens have been lacking to date. Therefore, the objective of the current study was to correlate PD-L1 expression in both TCs and ICs between matched cytology cell block and surgical specimens and investigate interobserver variability within this context to determine whether cell blocks are appropriate for the evaluation of PD-L1 IHC in the clinical setting.
MATERIALS AND METHODS

Patient Selection and Clinical and Pathologic Characteristics
Consecutive patients who were treated for advanced lung carcinomas at Brigham and Women's Hospital and the Dana-Farber Cancer Institute between January 2015 and June 2016 for whom surgical and cytology samples of the lung malignancy were available were selected, with approval of the institutional review board of Brigham and Women's Hospital. Archival pathology material for each patient, when available, was analyzed retrospectively for PD-L1 IHC and the results were correlated between matching surgical and cytology specimens. Demographic and clinical information was obtained from the electronic medical record.
Cell Block Preparation
Cell blocks were prepared using the plasma-thrombin method. In brief, after washing in RPMI and centrifugation Original Article at 1800 revolutions per minute for 4 minutes, fine-needle aspiration (FNA) specimen cell pellets were mixed with equal parts plasma and thrombin to form a clotted pellet, which then was placed in a cassette and fixed in formalin for 4 hours. For non-FNA specimens, the procedure was followed as above using 1 drop of plasma and thrombin per case. Fixed tissue then was processed on the Peloris II Premium Tissue Processing System (Leica Biosystems, Buffalo Grove, Illinois) for a 4-hour cycle. Cell block sections were cut at 4-lm intervals and stained with hematoxylin and eosin using standard methods.
PD-L1 IHC
IHC for PD-L1 was performed on 4-mm thick formalinfixed paraffin-embedded whole-tissue sections or cytology cell blocks after pressure cooker heat-induced epitope retrieval (0.01 M citrate buffer [pH 6.0]) using a rabbit monoclonal antibody (clone E1L3N [1:100 dilution]; Cell Signaling Technology, Danvers, Massachusetts) and the Dako EnVision Flex detection system (Agilent Technologies, Santa Clara, California). Appropriate positive and negative controls were examined along with study cases. PD-L1 expression was evaluated independently in TCs and ICs in both cytopathology and matching surgical specimens by 2 pulmonary pathologists (L.M.S. and M.V.), one of whom (M.V.) also has expertise in cytopathology. Complete or incomplete membranous staining in TCs and ICs was considered positive, regardless of intensity, as previously described (Fig. 1) . 21 PD-L1 staining was scored as the percentage of cells present as follows: absent staining (0%), <1% staining, 1% to 5% staining, and in increments of 5% thereafter. A tumor cell count of at least 100 cells was required for adequate evaluation of TCs in surgical and cytology specimens.
Statistical Analysis
Categorical data were analyzed using the Fisher exact test, and continuous data were analyzed using the MannWhitney-Wilcoxon test. PD-L1 TC and IC proportion scores were calculated by averaging data collected by both observers. Bland-Altman plots were constructed to visually assess the agreement between the 2 observers using the concepts of limits of agreement. The intraclass correlation coefficient (ICC) was calculated based on variance components of a mixed effects model to assess the agreement between the 2 observers. This model included observers as a fixed effect to evaluate the differences among the observers, and subjects as a random effect to account for correlation among measurements from the 2 observers on the same subject. The Spearman correlation coefficient was used to assess the correlation in PD-L1 expression in TCs and ICs between cytopathology and surgical specimens. All statistical analyses were performed using R statistical software (RStudio Team, RStudio Inc, Boston, Massachusetts [http://www.rstudio.com/]), with a predetermined P value of .05 to determine statistical significance. No adjustments were made for multiple comparisons.
RESULTS
Patient Clinical and Pathologic Characteristics
Patient clinical and pathologic characteristics are summarized in Table 1 . A total of 46 patients were treated for advanced lung carcinomas between January 2015 and June 2016, and included 13 men (28%) and 33 women (72%), with a median age of 67.5 years (range, 42-90 years). A total of 56 cytology specimens with 46 paired surgical specimens were obtained from study patients, 6 of whom underwent multiple cytology sampling procedures. Cytology specimens included 43 FNA specimens, 9 pleural effusion specimens, 2 bronchial brushing specimens, and 2 forceps rinses obtained during endobronchial biopsy. The 46 surgical specimens included 27 core needle biopsies, 12 endobronchial biopsies, 4 wedge resections, and 10 lobectomies. Forty-one of the paired specimens were obtained from the same site. Of the 56 paired specimens, 37 were obtained concurrently, 12 cytology specimens were obtained before the surgical specimen, and 7 cytology specimens were obtained subsequent to the surgical specimen. The median time between specimens was 22 days (range, 6-60 days) in patients whose cytology samples preceded surgical sampling and 254 days (range, 16-735 days) in patients whose cytology samples were obtained after surgical sampling. Of the 19 patients who underwent cytology and surgical sampling at different times, 9 received interval treatment between sampling procedures. Two of 12 patients whose cytology samples were obtained before surgical sampling received interval treatment: 1 patient who received second-line therapy with osimertinib and savolitinib and 1 patient who previously had been receiving and continued to receive erlotinib between sampling procedures. All patients whose cytology samples were obtained after surgical sampling received interval treatment, including 5 patients who PD-L1 Staining in Cytology Specimens/Russell-Goldman et al
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received traditional first-line chemotherapy, 1 patient who received second-line radiotherapy, and 1 patient who received second-line carboplatin and pemetrexed after treatment with erlotinib.
The majority of patients were former or current smokers (65%), had adenocarcinoma histology (76%), and had no known targetable mutations among those cases for which gene sequencing was available (38%). Patients with PD-L1 expression of <1% in TCs tended to be older (see Supporting Information Table 1 ). Female sex and KRAS mutations were more common among patients with high tumor PD-L1 expression (present in 79% and 67%, respectively, of patients with 50% PD-L1 expression) (Table 1) , and this relationship persisted using a lower threshold of 1% for PD-L1 positivity (present in 69% and 36%, respectively, of patients with 1% PD-L1 expression) (see Supporting Information Table 1 ). No other demographic characteristics were found to differ among patients with high TC or IC PD-L1 expression.
Comparison of TC PD-L1 Expression Between Cytology and Surgical Specimens
Examples of TC PD-L1 staining in cytology and surgical specimens are shown in Figures 1A to 1D . A total of 29 surgical specimens (63%) demonstrated PD-L1 IHC positivity in TCs at a threshold of 1%, and 14 (30%) demonstrated expression in 50% of cells. The average PD-L1 positivity was 28% in surgical specimens and 21% in cytology specimens (standard deviations [SDs] of 37% and 33%, respectively). Interobserver agreement was very high when scoring PD-L1 expression in TCs in both surgical specimens (ICC, 0.96) ( Fig. 2A) and cytology specimens (ICC, 0.96) (Fig. 2B) . Comparison of PD-L1 expression in TCs between surgical and cytology specimens demonstrated moderate correlation (Spearman r, 0.69) (Fig. 3A) , and was stronger when examining FNA specimens only (Spearman r, 0.78) (Fig. 3B) . The current study cohort included 15 paired cytology and surgical specimens from different anatomical sites and 41 paired cytology and surgical specimens from the same anatomical site. Therefore, we analyzed PD-L1 expression in TCs in cytology specimens obtained from different anatomical sites as the 
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surgical specimens, and determined that, compared with specimens taken from the same anatomical site (Spearman r, 0.84) (Fig. 4A) , the correlation between these specimens was much lower (Spearman r, 0.08) (Fig. 4B) .
Comparison of IC PD-L1 Expression Between Cytology and Surgical Specimens
Examples of IC PD-L1 staining in cytology and surgical specimens are shown in Figures 1E to 1H . Due to the proposed importance of PD-L1 expression in ICs as a predictive biomarker, 18 we also evaluated PD-L1 IHC staining in ICs in both cytology and surgical specimens. A total of 27 surgical specimens (57%) demonstrated IC PD-L1 IHC positivity at a threshold of 1%, and 9 (20%) demonstrated expression in 10% of cells. The average amount of PD-L1 positivity in ICs was 5% in surgical specimens and 8% in cytology specimens (SDs of 7% and 15%, respectively). There was moderate interobserver agreement, respectively, when scoring PD-L1 expression in ICs in surgical specimens (ICC, 0.47) (Fig. 2C ) and cytology specimens (ICC, 0.67) (Fig. 2D) . Comparison of PD-L1 expression in ICs between surgical and cytology specimens demonstrated negligible correlation of IC PD-L1 expression among the 2 specimen types (Spearman r, 0.14) (Fig.  3C) , which slightly improved when considering FNA specimens only (Spearman r, 0.23) (Fig. 3D) . Correlation of IC PD-L1 staining between specimens obtained from either the same anatomical site or different sites was low (Spearman r, 0.17 and -0.001, respectively) (Figs. 4C and 4D). Interval treatment in patients whose surgical and cytology specimens were obtained at different times did not appear to affect PD-L1 staining.
Evaluation of Interobserver Agreement Regarding PD-L1 Expression With Respect to Clinical Cutoff Points
Clinical studies have evaluated PD-L1 IHC using various cutoff values to define "positivity," most commonly 1% or 50% for TCs and 1% or 10% for ICs. 16, 18 Interobserver agreement at different diagnostic thresholds is summarized in Table 2 . 18 Agreement regarding TC PD-L1 expression between observers was higher at a 50% threshold compared with a 1% threshold in both surgical specimens (98% vs 79%, respectively) and cytology specimens (96% vs 88%, respectively). Similarly, agreement regarding IC PD-L1 expression was higher at a threshold of 10% compared with 1% in both surgical specimens (77% and 75%, respectively) and cytology specimens (82% and 70%, respectively). To determine whether specimen type affected the agreement between observers at different clinical cutoff values, we also compared PD-L1 positivity between specimens, and demonstrated that there was no significant difference in either TC or IC PD-L1 expression at either the 1% or 50% cutoff values for TCs among different types of surgical and cytology specimens, or at a cutoff value of 1% for ICs in cytology specimens (Table 3) . Direct sampling (FNA) yielded higher rates of IC PD-L1 positivity among cytology specimens at a cutoff value of 10%, as did larger surgical specimens (resections vs biopsies) at both cutoff values (Table 3) .
DISCUSSION
Recent clinical trials have demonstrated the efficacy of PD-1 checkpoint blockade in the treatment of patients with advanced NSCLC. 18, 20, 22 In current practice, PD-L1 IHC assays are used to make the decision to pursue anti-PD-1 or anti-PD-L1 immune therapy in patients with advanced NSCLC. Although expression thresholds have been established to select patients for treatment with pembrolizumab in clinical practice, PD-L1 IHC is widely acknowledged to lack optimal sensitivity and specificity as a biomarker, and other tumor characteristics, such as high tumor mutational burden, may interact with PD-L1 expression to modify patient response to immune checkpoint therapy. 23 Therefore, a variety of approaches to patient selection for immunotherapy continue to be studied. Clinical trials to date have used surgical specimens for PD-L1 IHC, and therefore the suitability of cytology specimens for PD-L1 IHC analysis has not been established. However, cytology specimens increasingly are being 
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April 2018 used for both the primary diagnosis of advanced lung malignancies and to perform ancillary studies, 24 and therefore IHC evaluation of PD-L1 expression in these specimens also will become more prevalent. Therefore, we evaluated the suitability of cytology specimens for evaluating PD-L1 expression by comparing PD-L1 staining in 56 matched cytology and surgical specimens from 47 patients with advanced lung malignancies.
The data from the current study indicate very high interobserver agreement regarding PD-L1 expression in TCs in both cytology and surgical specimens, and a moderate correlation between PD-L1 expression in TCs between paired cytology and surgical specimens that was stronger when FNA specimens were analyzed separately. We also found moderate interobserver agreement regarding PD-L1 expression in ICs in cytology specimens, confirming previous reports of less agreement among pathologists when scoring PD-L1 expression in ICs. 25, 26 Furthermore, there was negligible correlation between PD-L1 expression in ICs between paired specimens, and this was improved Abbreviation: PD-L1, programmed death-ligand 1. a A PD-L1 score of 10% in tumor-infiltrating immune cells has been associated with an increased response to treatment with atezolizumab.
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Original Article only slightly when considering FNA specimens only, indicating that cytology specimens are not suitable for evaluating PD-L1 expression in ICs. There are several possible explanations for this finding, including the absence of architecture and consequently variable thresholds for determining whether an IC truly is "tumor-associated" or not in cytology specimens, spatial heterogeneity of ICs, possible difficulty in discerning a TC versus an IC on a cell block, and the sometimes low level of PD-L1 expression in ICs. It is an important observation to consider in practice and warrants further investigation of the tumor microenvironment because some studies have emphasized the role of PD-L1 positivity in ICs in response to treatment 18 and in prognosis. 27 The potential issue of intratumoral heterogeneity in PD-L1 expression, which may impact patient management, recently has been described, and although the majority of studies have demonstrated some heterogeneity in PD-L1 expression within a tumor, comparison of PD-L1 expression between small biopsy and surgical resection specimens has yielded conflicting results, and therefore the nature and extent of heterogeneity is uncertain. 21, 25, [27] [28] [29] For example, some studies have demonstrated heterogeneity between microarray cores from the same block, 21 whereas others have shown that although heterogeneity exists between different parts of a tumor, tumor within a single block is relatively homogeneous. 25 In addition, 2 recent studies have demonstrated discrepancies in PD-L1 expression between primary tumors and lymph node metastases in 30% to 38% of NSCLC cases, suggesting that tumor heterogeneity may affect PD-L1 assessment of a tumor at different anatomical sites. 30, 31 The results of these studies led us to investigate whether there was a difference in the correlation of PD-L1 expression between surgical samples and cytology samples collected from different anatomical sites compared with cytology samples collected from the same site. We found that although there was a strong positive correlation of PD-L1 staining in TCs between cytology and surgical specimens taken from the same anatomical site, this correlation was lost when comparing PD-L1 expression in cytology and surgical specimens from different anatomical sites. Conversely, there was negligible correlation of IC PD-L1 expression noted between cytology and surgical specimens from either the same or different anatomical sites. In addition, the type of specimen and the amount of tissue examined previously has been shown to affect the interpretation of PD-L1 IHC. 28, 29 Although we found no differences in TC staining between different types of cytology or surgical specimens, the majority of the cases demonstrating IC positivity were FNA specimens and surgical resection specimens. These findings suggest that larger amounts of tissue may be more informative regarding the PD-L1 status of ICs, and that IC PD-L1 staining should be interpreted with caution in small tissue biopsies and cytology specimens. In the assessment of intratumoral heterogeneity of PD-L1 staining, there is some evidence that using a lower threshold of 10% for PD-L1 positivity in small biopsies results in a more accurate assessment of overall tumor PD-L1 expression in surgical resection specimens compared with a threshold of 50%. 21 However, the results of the current study suggest that interobserver agreement regarding PD-L1 staining in TCs is less robust at a lower cutoff value of 1% in both surgical and cytology specimens, and in IC staining in cytology specimens. These combined findings highlight the need for further evaluation and the PD-L1 Staining in Cytology Specimens/Russell-Goldman et al
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April 2018 establishment of biologically relevant but clinically practical cutoff values for PD-L1 IHC in small biopsy and cytology specimens, because the majority of patients with lung malignancies will not undergo surgical resection when presenting with advanced disease. Limitations of the current study include the use of a laboratory-developed test using the E1L3N anti-PD-L1 antibody rather than clinically established companion or complementary PD-L1 assays, as well as the limited number of patients with recent matched surgical and cytology specimens amenable to PD-L1 IHC. However, E1L3N has been demonstrated to perform similarly to other complementary diagnostics in terms of concordance and reproducibility in cross-institutional studies, 26 and the internal consistency and high interobserver agreement in the current study likely makes its findings applicable to other PD-L1 IHC assays.
The results of the current study demonstrated that there is significant correlation of PD-L1 IHC staining of TCs, but not of ICs, between surgical and cytology specimens. It is important to note that this correlation is strongest in FNA specimens and among specimens obtained from the same anatomical site, and does not appear to differ between different types of cytology specimens. Therefore, cytology specimens are a valid substrate for the evaluation of PD-L1 expression in TCs in patients with advanced lung carcinomas, although the appropriate clinical cutoff values and the role of cytology PD-L1 staining of ICs in these individuals remain to be defined further.
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